Diabetes Drug - Tirzepatide Gets FDA Approval for Weight Loss

References:

1. Why Does Obesity Cause Diabetes? - (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740746/)
2. FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management - (https://pubmed.ncbi.nlm.nih.gov/37966831/)
3. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review - (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268041/)
4. Tirzepatide: A Systematic Update - (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741068/)
5. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes - (https://pubmed.ncbi.nlm.nih.gov/34170647/)
6. Tirzepatide injection - (https://medlineplus.gov/druginfo/meds/a622044.html)
7. FDA Approves New Medication for Chronic Weight Management - (https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management)
8. Tirzepatide: Overview - (https://www.ncbi.nlm.nih.gov/books/NBK585056/)
9. Zepbound (Tirzepatide) Injection, for subcutaneous use - (https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf)

Author: Dr. Janani Priya

Editor: Dr. Sunil Shroff

Technically Checked by: Lingaraj